Stock Analysis
As global markets grapple with geopolitical tensions and consumer spending concerns, investors are keeping a close eye on economic indicators and policy shifts. Amidst this backdrop, the allure of penny stocks remains strong for those seeking potential high returns from smaller or newer companies. Though often seen as relics of past market eras, these stocks can offer affordability and growth potential when backed by solid financial foundations.
Top 10 Penny Stocks
Name | Share Price | Market Cap | Financial Health Rating |
DXN Holdings Bhd (KLSE:DXN) | MYR0.525 | MYR2.61B | ★★★★★★ |
Bosideng International Holdings (SEHK:3998) | HK$3.88 | HK$44.54B | ★★★★★★ |
Datasonic Group Berhad (KLSE:DSONIC) | MYR0.305 | MYR848.56M | ★★★★★★ |
Angler Gaming (NGM:ANGL) | SEK3.94 | SEK295.44M | ★★★★★★ |
T.A.C. Consumer (SET:TACC) | THB4.16 | THB2.5B | ★★★★★★ |
Warpaint London (AIM:W7L) | £3.95 | £319.11M | ★★★★★★ |
Hil Industries Berhad (KLSE:HIL) | MYR0.855 | MYR283.81M | ★★★★★★ |
Foresight Group Holdings (LSE:FSG) | £3.95 | £450.28M | ★★★★★★ |
Embark Early Education (ASX:EVO) | A$0.79 | A$144.95M | ★★★★☆☆ |
Next 15 Group (AIM:NFG) | £3.05 | £303.34M | ★★★★☆☆ |
Click here to see the full list of 5,712 stocks from our Penny Stocks screener.
Let's uncover some gems from our specialized screener.
CapAllianz Holdings (Catalist:594)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: CapAllianz Holdings Limited is an investment holding company involved in the exploration, development, production, and drilling of oil and gas in Singapore and Thailand, with a market cap of SGD18.41 million.
Operations: The company's revenue is derived from its Oil and Gas segment, generating $2.11 million, and Technical Services, contributing $2.12 million.
Market Cap: SGD18.41M
CapAllianz Holdings Limited, with a market cap of SGD18.41 million, reported revenue of US$2.15 million for the half year ending December 31, 2024, showing slight growth from the previous year. Despite being unprofitable and having negative return on equity (-0.64%), it has managed to reduce losses over the past five years by a very large margin annually and remains debt-free with adequate short-term asset coverage for liabilities. However, its share price is highly volatile and its board lacks seasoned experience with an average tenure of 2.8 years. The company maintains sufficient cash runway for over three years based on current free cash flow trends.
- Unlock comprehensive insights into our analysis of CapAllianz Holdings stock in this financial health report.
- Learn about CapAllianz Holdings' historical performance here.
Nykode Therapeutics (OB:NYKD)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies, with a market cap of NOK851.63 million.
Operations: The company generates revenue from its Pharmaceuticals segment, totaling $4.37 million.
Market Cap: NOK851.63M
Nykode Therapeutics, with a market cap of NOK851.63 million, is focused on developing immunotherapies and has reported revenue of US$4.37 million from its Pharmaceuticals segment. Despite being unprofitable and experiencing increased losses over the past five years, Nykode remains debt-free with robust short-term asset coverage for liabilities. Recent announcements highlight promising data from its cancer vaccine VB10.16 in combination with atezolizumab for HPV16-positive cervical cancer, showing potential synergistic effects and extended clinical benefits in trials. The company is streamlining its board to align financial resources better while extending cash runway into 2030 amidst volatile share prices.
- Jump into the full analysis health report here for a deeper understanding of Nykode Therapeutics.
- Explore Nykode Therapeutics' analyst forecasts in our growth report.
Country Group Holdings (SET:CGH)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Country Group Holdings Public Company Limited, with a market cap of THB2.16 billion, primarily operates in the securities business through its subsidiaries in Thailand.
Operations: The company generates revenue from various segments, including THB29.11 million from Investment Banking, THB319.71 million from Securities and Derivatives Trading, and THB959.57 million from Securities and Derivatives Brokerage.
Market Cap: THB2.16B
Country Group Holdings, with a market cap of THB2.16 billion, has recently turned profitable, distinguishing itself in the capital markets sector. The company generates significant revenue from its securities and derivatives brokerage segment (THB959.57 million), highlighting a strong operational focus. Despite an increase in debt-to-equity ratio over five years to 30.4%, its debt is well covered by operating cash flow (23.2%), and short-term assets exceed both short-term and long-term liabilities significantly. The management team and board are experienced, with average tenures exceeding a decade, supporting stable governance amidst earnings volatility challenges over recent years.
- Click here and access our complete financial health analysis report to understand the dynamics of Country Group Holdings.
- Review our historical performance report to gain insights into Country Group Holdings' track record.
Taking Advantage
- Discover the full array of 5,712 Penny Stocks right here.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Jump on the AI train with fast growing tech companies forging a new era of innovation.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Nykode Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About OB:NYKD
Nykode Therapeutics
A clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies.